Assembly Biosciences (ASMB) risk factors
Item 1A of every Assembly Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors40 risks6 new5 dropped8 reworded
Assembly Biosciences added specific risks regarding US government shutdowns delaying international clinical sample customs clearance. Manufacturing reliance on third-party suppliers for active pharmaceutical ingredients was newly emphasized. Gilead's ownership stake decreased from approximately 29.9% to 28% in the ongoing collaboration.
Filed Mar 19, 2026 - FY2024 10-K risk factors39 risks
Assembly Biosciences faces intense reliance on its October 2023 Gilead collaboration agreement for clinical development and commercialization funding. The company has a history of operating losses, depends on third-party manufacturers and CROs, and operates in competitive markets covering HBV, HDV, and recurrent genital herpes.
Filed Mar 20, 2025